• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌的完全性转移灶切除术:五个实体器官部位的比较

Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites.

作者信息

Jakubowski Christopher D, Vertosick Emily A, Untch Brian R, Sjoberg Daniel, Wei Elizabeth, Palmer Frank L, Patel Snehal G, Downey Robert J, Strong Vivian E, Russo Paul

机构信息

Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

J Surg Oncol. 2016 Sep;114(3):375-9. doi: 10.1002/jso.24327. Epub 2016 Jun 23.

DOI:10.1002/jso.24327
PMID:27338155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5104341/
Abstract

BACKGROUND AND OBJECTIVES

Patients with metastatic RCC can undergo metastasectomy to improve survival time. Our goal was to provide and compare characteristics and oncological outcomes of RCC patients who underwent complete metastasectomy at a single organ site.

METHODS

A total of 138 RCC patients were identified as undergoing complete metastasectomy at a single organ site including adrenal, lung, liver, pancreas, or thyroid. Competing risk regression analysis was used to assess RFS and CSS adjusting for several covariates.

RESULTS

In this highly selected cohort, RFS and CSS was 27% and 84% at 5 years following metastasectomy, respectively. Univariate analysis revealed that removal of multiple tumors, younger age, and a shorter interval between nephrectomy and metastasis was associated with worse RFS. Larger tumors and sarcomatoid histology at nephrectomy was associated with worse CSS. We found no evidence that metastases at the time of RCC diagnosis influenced recurrence or survival. Tumor size, number of metastases resected, and time from nephrectomy to first recurrence was significantly different, but recurrence rates were not found to be significantly different, when compared across all organ sites.

CONCLUSIONS

These findings inform clinical and surgical management of select RCC patients with isolated metastasis to one of several organ sites. J. Surg. Oncol. 2016;114:375-379. © 2016 Wiley Periodicals, Inc.

摘要

背景与目的

转移性肾细胞癌(RCC)患者可接受转移灶切除术以延长生存时间。我们的目标是提供并比较在单一器官部位接受完全转移灶切除术的RCC患者的特征及肿瘤学结局。

方法

共纳入138例在单一器官部位(包括肾上腺、肺、肝、胰腺或甲状腺)接受完全转移灶切除术的RCC患者。采用竞争风险回归分析评估无复发生存期(RFS)和总生存期(CSS),并对多个协变量进行校正。

结果

在这个经过高度筛选的队列中,转移灶切除术后5年的RFS和CSS分别为27%和84%。单因素分析显示,切除多个肿瘤、年龄较轻以及肾切除术与转移之间的间隔时间较短与较差的RFS相关。肾切除时肿瘤较大和肉瘤样组织学类型与较差的CSS相关。我们没有发现证据表明RCC诊断时的转移会影响复发或生存。在所有器官部位进行比较时,肿瘤大小、切除的转移灶数量以及从肾切除到首次复发的时间有显著差异,但未发现复发率有显著差异。

结论

这些发现为部分孤立转移至多个器官部位之一的RCC患者的临床和外科治疗提供了依据。《外科肿瘤学杂志》2016年;114:375 - 379。© 2016威利期刊公司。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b11/5104341/1aa5d657c8c4/nihms823718f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b11/5104341/1c893f1ba830/nihms823718f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b11/5104341/1aa5d657c8c4/nihms823718f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b11/5104341/1c893f1ba830/nihms823718f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b11/5104341/1aa5d657c8c4/nihms823718f2.jpg

相似文献

1
Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites.肾细胞癌的完全性转移灶切除术:五个实体器官部位的比较
J Surg Oncol. 2016 Sep;114(3):375-9. doi: 10.1002/jso.24327. Epub 2016 Jun 23.
2
Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).肾细胞癌(RCC)非典型转移的外科治疗。
BJU Int. 2012 Dec;110(11 Pt B):E559-63. doi: 10.1111/j.1464-410X.2012.11271.x. Epub 2012 May 28.
3
Spinal metastasectomy of renal cell carcinoma: A 16-year single center experience with a minimum 3-year follow-up.肾细胞癌脊柱转移瘤切除术:一项单中心16年经验,至少随访3年。
J Surg Oncol. 2016 Apr;113(5):587-92. doi: 10.1002/jso.24186. Epub 2016 Feb 5.
4
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.嫌色细胞肾细胞癌(RCC):大型多中心系列中的肿瘤学结果和预后因素。
BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.
5
The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma.原发性肿瘤对转移性肾细胞癌肺转移瘤切除术长期疗效的影响。
Thorac Cardiovasc Surg. 2012 Sep;60(6):390-7. doi: 10.1055/s-0031-1295572. Epub 2011 Dec 29.
6
Survival after complete surgical resection of multiple metastases from renal cell carcinoma.肾细胞癌多发转移完全手术后的生存情况。
Cancer. 2011 Jul 1;117(13):2873-82. doi: 10.1002/cncr.25836. Epub 2011 Jan 10.
7
Pulmonary metastasectomy from renal cell carcinoma including 3 cases with sarcomatoid component.肾细胞癌肺转移瘤切除术,包括3例伴有肉瘤样成分的病例。
Gen Thorac Cardiovasc Surg. 2016 Mar;64(3):149-52. doi: 10.1007/s11748-016-0623-6. Epub 2016 Jan 25.
8
Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.手术治疗转移性肾细胞癌的临床预后因素的生存和影响。
Eur Urol. 2013 Apr;63(4):646-52. doi: 10.1016/j.eururo.2012.09.037. Epub 2012 Sep 24.
9
[Pulmonary resections for metastatic renal cell carcinoma in Iceland].[冰岛转移性肾细胞癌的肺切除术]
Laeknabladid. 2008 May;94(5):377-81.
10
Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era.肾细胞癌转移灶的手术治疗:靶向治疗时代的治疗结果及鲁汶-乌迪内预后分组的初步评估
Scand J Urol. 2018 Oct-Dec;52(5-6):419-426. doi: 10.1080/21681805.2018.1553893. Epub 2019 Jan 20.

引用本文的文献

1
Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review.治疗肾细胞癌不同转移部位的选择:综述。
Medicine (Baltimore). 2024 May 24;103(21):e38268. doi: 10.1097/MD.0000000000038268.
2
The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study.转移性非透明细胞肾细胞癌行转移灶切除术的生存获益:一项回顾性队列研究。
World J Urol. 2024 Apr 25;42(1):259. doi: 10.1007/s00345-024-04973-8.
3
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.

本文引用的文献

1
EAU guidelines on renal cell carcinoma: 2014 update.EAU 指南:肾细胞癌. 2014 年更新版.
Eur Urol. 2015 May;67(5):913-24. doi: 10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21.
2
Local treatments for metastases of renal cell carcinoma: a systematic review.局部治疗肾细胞癌转移:系统评价。
Lancet Oncol. 2014 Nov;15(12):e549-61. doi: 10.1016/S1470-2045(14)70235-9. Epub 2014 Oct 26.
3
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.在靶向治疗时代,细胞减灭性肾切除术的应用和患者生存。
帕唑帕尼对比安慰剂用于转移性肾细胞癌患者的随机、双盲 III 期研究:ECOG-ACRIN E2810 试验,这些患者在转移灶切除术之后没有疾病证据。
J Clin Oncol. 2024 Jun 10;42(17):2061-2070. doi: 10.1200/JCO.23.01544. Epub 2024 Mar 26.
4
SABR for oligometastatic renal cell carcinoma.立体定向体部放疗用于寡转移肾细胞癌
Clin Transl Radiat Oncol. 2024 Feb 1;45:100739. doi: 10.1016/j.ctro.2024.100739. eCollection 2024 Mar.
5
Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review.靶向治疗和免疫治疗时代转移性肾细胞癌的外科转移灶切除术:叙述性综述。
World J Urol. 2024 Jan 20;42(1):51. doi: 10.1007/s00345-023-04706-3.
6
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study.胰腺及其他部位转移性肾细胞癌——一项多中心回顾性研究
EClinicalMedicine. 2023 Jun 1;60:102018. doi: 10.1016/j.eclinm.2023.102018. eCollection 2023 Jun.
7
Surgical Approach in Metastatic Renal Cell Carcinoma: A Literature Review.转移性肾细胞癌的手术治疗方法:文献综述
Cancers (Basel). 2023 Mar 16;15(6):1804. doi: 10.3390/cancers15061804.
8
The Decision to Surgically Resect Recurrent Renal Cell Carcinoma: More Evidence that Careful Case Selection by Surgeons Is Associated with Better Survival.手术切除复发性肾细胞癌的决策:更多证据表明外科医生仔细的病例选择与更好的生存率相关。
Eur Urol Open Sci. 2023 Jan 31;49:90-91. doi: 10.1016/j.euros.2023.01.006. eCollection 2023 Mar.
9
Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy.寡转移肾细胞癌的转移灶定向立体定向放疗:放疗消除的肿瘤负荷程度。
World J Urol. 2021 Nov;39(11):4183-4190. doi: 10.1007/s00345-021-03742-1. Epub 2021 May 27.
10
A Plea for Surgery in Pancreatic Metastases from Renal Cell Carcinoma: Indications and Outcome from a Multicenter Surgical Experience.肾癌胰腺转移行手术治疗的呼吁:多中心手术经验的指征与结果
J Clin Med. 2020 Oct 13;9(10):3278. doi: 10.3390/jcm9103278.
Int J Cancer. 2014 May 1;134(9):2245-52. doi: 10.1002/ijc.28553.
4
Pancreatic metastasectomy: the Memorial Sloan-Kettering experience and a review of the literature.胰腺转移瘤切除术:纪念斯隆-凯特琳癌症中心的经验和文献回顾。
J Surg Oncol. 2014 Jan;109(1):28-30. doi: 10.1002/jso.23460. Epub 2013 Oct 7.
5
Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.细胞因子和靶向治疗时代新诊断转移性肾细胞癌的疾病特异性生存。
PLoS One. 2013 May 3;8(5):e63341. doi: 10.1371/journal.pone.0063341. Print 2013.
6
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.肉瘤样肾细胞癌:生物学及当前治疗策略的全面综述。
Oncologist. 2012;17(1):46-54. doi: 10.1634/theoncologist.2011-0227. Epub 2012 Jan 10.
7
Survival after complete surgical resection of multiple metastases from renal cell carcinoma.肾细胞癌多发转移完全手术后的生存情况。
Cancer. 2011 Jul 1;117(13):2873-82. doi: 10.1002/cncr.25836. Epub 2011 Jan 10.
8
Surgical treatment of renal cell cancer liver metastases: a population-based study.肾细胞癌肝转移的外科治疗:一项基于人群的研究。
Ann Surg Oncol. 2011 Jul;18(7):1932-8. doi: 10.1245/s10434-010-1526-x. Epub 2011 Feb 23.
9
Prognostic factors for survival after surgery for adrenal metastasis.肾上腺转移瘤手术后生存的预后因素。
Eur J Surg Oncol. 2010 Jul;36(7):699-704. doi: 10.1016/j.ejso.2010.04.002. Epub 2010 May 7.
10
Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis.肝切除术治疗转移性肾癌可延长患者生存时间:回顾性对比分析 12 年结果。
World J Urol. 2010 Aug;28(4):543-7. doi: 10.1007/s00345-010-0560-4. Epub 2010 May 4.